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Abstract
Objectives: Based on multi-domain classification of Parkinson disease (PD)
subtypes, we sought to determine the key features that best differentiate sub-
types and the utility of PD subtypes to predict clinical milestones. Methods:
Prospective cohort of 162 PD participants with ongoing, longitudinal follow-
up. Latent class analysis (LCA) delineated subtypes based on score patterns
across baseline motor, cognitive, and psychiatric measures. Discriminant analy-
ses identified key features that distinguish subtypes at baseline. Cox regression
models tested PD subtype differences in longitudinal conversion to clinical
milestones, including deep brain stimulation (DBS), dementia, and mortality.
Results: LCA identified distinct subtypes: “motor only” (N = 63) characterized
by primary motor deficits; “psychiatric & motor” (N = 17) characterized by
prominent psychiatric symptoms and moderate motor deficits; “cognitive &
motor” (N = 82) characterized by impaired cognition and moderate motor def-
icits. Depression, executive function, and apathy best discriminated subtypes.
Since enrollment, 22 had DBS, 48 developed dementia, and 46 have died.
Although there were no subtype differences in rate of DBS, dementia occurred
at a higher rate in the “cognitive & motor” subtype. Surprisingly, mortality risk
was similarly elevated for both “cognitive & motor” and “psychiatric & motor”
subtypes compared to the “motor only” subtype (relative risk = 3.15, 2.60).
Interpretation: Psychiatric and cognitive features, rather than motor deficits,
distinguish clinical PD subtypes and predict greater risk of subsequent dementia
and mortality. These results emphasize the value of multi-domain assessments
to better characterize clinical variability in PD. Further, differences in dementia
and mortality rates demonstrate the prognostic utility of PD subtypes.
Introduction
Parkinson disease (PD) causes motor, cognitive, and psy-
chiatric dysfunction that impair quality of life, health,
and lifespan. These clinical features do not occur in isola-
tion, but rather in combination. Specific patterns of
motor, cognitive, and psychiatric dysfunction may yield
distinct PD subtypes, potentially reflecting differences in
neuropathology,1–5 that predict prognosis and treatment
response.
The majority of clinically derived subtyping studies
focus on motor deficits, dichotomizing PD into tremor
dominant or nontremor dominant (akinetic-rigid or pos-
tural instability with gait difficulty [PIGD]).6,7 However,
cognitive and psychiatric features also contribute to qual-
ity of life and may differentiate subtypes.8–10 Thus, multi–
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domain approaches could have greater clinical utility than
single-domain (e.g., motor) classifications.
Multi-domain classifications, including motor, cogni-
tive, and psychiatric measures, permit broader subtypes
capturing the full spectrum of clinical manifestations.
However, most multi-domain studies utilized cognitive
screening measures (e.g., Montreal Cognitive Assess-
ment),11–13 categorized participants based on cognitive
status (e.g., mild cognitive impairment [MCI]),14
included only a single psychiatric rating,11,15,16 or com-
bined cognitive and psychiatric function into “non-mo-
tor” symptoms.17 Even with comprehensive assessments,
few studies considered which features best discriminate
subtypes. Further, most studies conducted behavioral
evaluations while participants were medicated12,14–16 (in-
troducing variability and potential medication effects),
focused on early-stage PD with limited clinical manifesta-
tions,2,11,12,18 or included participants with dementia,13–16
precluding the ability to predict dementia. In fact, few
multi-domain studies report longitudinal follow-up2,14,19
thus limiting insight regarding the utility of PD subtypes
to predict clinically meaningful outcomes20 such as
dementia or mortality. Predicting progression across PD
subtypes could guide prognosis and improve clinical care.
Therefore, this study aims to (1) classify PD subtypes
based on comprehensive, multi-domain clinical evalua-
tions at baseline; (2) determine the specific features that
best discriminate subtypes at baseline; and (3) predict
longitudinal rates for clinical outcomes, including deep
brain stimulation (DBS), dementia, and mortality across
subtypes. We applied latent class analysis (LCA) to base-
line motor, cognitive, and psychiatric measures in a large,
prospective longitudinal sample of nondemented PD par-
ticipants. DBS, dementia, and mortality rates were com-
pared across baseline PD subtypes to determine clinical
utility.
Methods
Standard protocol approvals, registrations,
and consents
The Washington University in St. Louis (WUSTL)
Human Research Protection Office approved this study.
All participants provided written informed consent.
Study overview
As part of a larger, on-going study, a prospective cohort
of 210 PD participants was recruited through the WUSTL
Movement Disorders Center and community between
January 2006 and September 2015. At study enrollment,
participants completed a comprehensive motor, cognitive
and clinical evaluation as described below, which is
repeated at follow-up visits. Longitudinal follow-up visits
occur every 1–3 years (average length of follow-
up = 4.8 years [SD = 2.4], range: 0–12 years) depending
on date of enrollment, for as long as the participant is
willing and able. If a participant is no longer able to
attend in-person testing sessions (e.g., severe cognitive or
motor deficits), clinical evaluations are completed over
the phone. Longitudinal follow-up is intended to con-
tinue until death and all participants agree to brain dona-
tion upon death. To date, 157 participants have
completed at least one follow-up visit, 12 have withdrawn
or are lost to follow-up, and 46 have died (see Fig. S1 for
study flowchart diagram). Here, we focus on the baseline
evaluation of 162 PD participants to identify clinical sub-
types and determine the key features that best distinguish
groups. Longitudinal clinical evaluations provide informa-
tion regarding the clinical milestones of DBS, conversion
to dementia, and mortality.
Participants
Parkinson disease diagnosis was based on modified Uni-
ted Kingdom PD Society Brain Bank clinical diagnostic
criteria with clear motor response to levodopa,21 to be
confirmed at autopsy. Two participants were drug naive
and excluded; two participants were found to not be PD
at autopsy, prior to these data analyses, and were
excluded. Dementia, defined as clinically significant cog-
nitive decline with functional impairment,22 was assessed
with the Clinical Dementia Rating evaluation (CDR)23;
33 PD participants met dementia criteria (CDR ≥ 1) at
baseline and were excluded from analyses. Additional
exclusion criteria were: other neurologic diagnosis, head
injury with loss of consciousness >5 min or neurologic
sequelae (N = 2), brain surgery (DBS exclusion only at
enrollment), schizophrenia, bipolar disorder, or incom-
plete baseline evaluations (N = 9). In total, baseline
behavioral evaluations from 162 nondemented PD were
included (Fig. S1; see Table 1 for baseline characteris-
tics).
Clinical evaluation
Clinical evaluations, with a collateral source and partici-
pants on medication, included the CDR (CDR ≥ 1 signi-
fies dementia, 0.5 indicates cognitive decline/impairment,
0 represents intact cognition), MMSE,24 Brief Smell Iden-
tification Test (BSIT),25 One Day Fluctuations,26 and
Epworth Sleepiness scale.27 Clinical assessments also
include review of medical history and general systems
review, including questions about current constipation,
orthostasis, or hallucinations, as well as surgical history
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(e.g., DBS). Symptom duration was computed in years
from motor symptom onset to baseline visit.
Motor assessments
After overnight withdrawal of PD medications, in the
practically defined “OFF” state, movement disorder spe-
cialists completed the Unified Parkinson Disease Rating
Scale motor subscale 3 (UPDRS-3). Tremor, bradykinesia,
rigidity, and PIGD subscores and levodopa equivalent
daily dose (LEDD) were computed.28,29 At the baseline
visit, 37 (23%) participants took dopamine agonists.
Cognitive assessments
Neuropsychological evaluations included tests of attention
(Digit Span;30 Digit Symbol30), memory (California Ver-
bal Learning Test-II, short form;31 Logical Memory32),
language (Boston Naming Test33), visuospatial (Judgment
of Line Orientation;34 Spatial Relations Test35) and execu-
tive function (Trail Making Test;36 Verbal Fluency-
Switching;37 Color-Word Interference37) while OFF PD
medications to avoid medication confounds.38 Age, sex,
and education-adjusted scaled scores, based on test manu-
als and published normative data, were converted to z-
scores and averaged within each domain.39 MCI was
determined using Movement Disorder Society Level II cri-
teria of at least two tests (>1.5 SD cutoff) within a single
domain or across multiple domains.40
Psychiatric assessments
Psychiatric function, assessed ON medication, was deter-
mined by self-rated Geriatric Depression Scale short form
(GDS)41 and Frontal Systems Behavior Scale – Apathy
subscale (FrSBe-A).42 Participants and a collateral source
completed the brief 12 item Neuropsychiatric Inventory
Questionnaire (NPIQ)43 to assess overall psychiatric func-
tion.
Statistical analyses
Identifying clinical subtypes
Latent class analysis (LCA) was used to identify PD sub-
types from baseline assessments. Analysis proceeds by
modeling 1, 2, 3, and up to k number of classes. Model
fit indices include: Akaike Information Criterion (AIC)
and Bayesian Information Criterion (BIC) where lower
relative scores indicate better model fit;44,45 Lo-Mendell-
Rubin Likelihood Ratio Test (LMR LRT)46 indicates
model fit with k classes compared to k1 classes where
P < 0.05 favors the k model; and relative entropy – a
measure of classification uncertainty (range: 0–1) with
higher values indicating greater classification certainty.
Class membership is assigned based on posterior proba-
bility values, with ≥0.7 indicating reliable individual class
assignment.47 Higher posterior probabilities for the
assigned class yields high overall model entropy. Model
selection also is based on meaningful class distinctions
and sufficient number of individuals per class to allow
further statistical analysis.48 Thus, the advantages of LCA
over more traditional cluster-based approaches are that
(1) LCA is a person-centered analysis that classifies indi-
viduals based on response pattern similarities to measured
indicator variables,49 whereas other clustering methods
are variable-centered and identify relationships among
variables50, as well as (2) LCA provides indices of model
fit and individual-level class membership probabilities for
greater classification certainty.
Indicator variables included the following baseline
scores: UPDRS-3 tremor, bradykinesia, rigidity, and
PIGD subscores; attention, memory, language, visuospa-
tial, and executive function cognitive domain scores; and
depression and apathy ratings, with age, sex, and educa-
tion covariates to avoid demographic-driven classifica-
tions. Indicator variables were normalized to z-scores,
based on sample distribution (motor subscores, GDS) or
published normative data (cognitive scores, FrSBe-Apathy
subscale).
Determining key features
To determine the key distinguishing features, discriminant
analyses, using indicator variables as well as other clinical
and demographic variables from the baseline assessments,
were conducted. One-way ANOVAs, nonparametric
Kruskal–Wallis, and chi-square tests compared PD sub-
types on indicator variables and additional clinical and
Table 1. Participant demographics and clinical characteristics at base-
line.
Clinical characteristics Mean (SD)
N 162
Sex (% male) 61.7%
Age (years) 66.1 (7.7)
Years of education 16.0 (2.5)
Duration of PD symptoms (years) 6.2 (3.8)
Age onset of PD 60.1 (8.0)
UPDRS-3 OFF total 24.2 (8.9)
LEDD 764 (493)
MMSE 28.3 (1.5)
UPDRS-3, Unified Parkinson Disease Rating Scale, motor subscale 3;
LEDD, levodopa equivalent daily dose; MMSE, Mini Mental Status
Exam.
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demographic information at baseline. Main effects of PD
subtype were followed by Tukey’s HSD post hoc pairwise
comparisons.
Conversion to clinical milestones
To determine PD subtype differences in clinical mile-
stones (DBS, dementia, mortality), multivariate Cox pro-
portional hazards regression models using the
longitudinal follow-up data were conducted, with censor-
ing based on last date of contact. Survival and events
were calculated as such for each milestone: for DBS,
events were defined as date of DBS and survival time was
calculated as time since baseline visit to most recent con-
tact; for dementia, events were defined as the date when a
participant received a CDR score ≥1, and survival time
was calculated as time since baseline visit to most recent
CDR; and for mortality, events were defined as date of
death, and survival time was calculated as time since
baseline to most recent contact. As follow-up visits may
only occur every three years, date of last contact (for the
DBS and mortality analyses) was based on most recent
contact from either a study visit, study contact, or clinical
visit.
LCA was conducted using MPlus (Muthen & Muthen,
Los Angeles CA). The longitudinal survival analyses (Cox
proportional hazards regression) were conducted in R
Version 3.5.2, SURVIVAL and SURVMINER packages (R
Foundation, Vienna Austria). Additional analyses were
conducted with PASW Version 25 (IBM, Chicago, IL). All
tests were 2-tailed and P < 0.05 defined statistical signifi-
cance.
Results
Baseline subtype classification
The 3-class LCA model provided the best overall fit
(Table S1) and high average posterior probabilities (0.91–
0.95), indicating high probability for assigned class mem-
bership. Classes captured three PD subtypes: (1) “motor
only” – mild motor deficits with intact cognition and
healthy psychological state (N = 63); (2) “psychiatric &
motor” – prominent depression and apathy, moderate
motor deficits, and intact cognition (N = 17); and (3)
“cognitive & motor” – impaired cognition, moderate
motor deficits, and relatively healthy psychiatric function
(N = 82).
The indicator variables discriminated PD subtypes,
with 98.3% correct classification, showing excellent sub-
type separation (Fig. 1A). Stepwise discriminant analysis
revealed that depression, executive function, apathy,
bradykinesia, visuospatial, attention, and PIGD best
discriminated PD subtypes with 95.1% correct classifica-
tion. Even with just depression, executive function, and
apathy, classification accuracy was 89.5%. Notably, tre-
mor scores did not distinguish subtypes despite their
frequent use in clinical subtyping. For comparison, we
classified participants according to the clinically derived
tremor dominant/PIGD motor subtypes,6 which yielded
19.8% tremor dominant, 59.9% PIGD, and 20.4%
unclassified/indeterminate. Thus, psychiatric and cogni-
tive features not only were the defining features for cer-
tain subtypes but also substantially increased
classification accuracy.
Baseline subtype differences
PD subtypes differed across all indicator variables
(ANCOVAs with age, sex, education covariates), except
tremor and memory (Fig. 1B; Table S2) at baseline. Post
hoc analyses (Table S2) revealed that the “motor only”
subtype had the lowest motor ratings, with no significant
differences between “psychiatric & motor” and “cognitive
& motor” subtypes. The “cognitive & motor” subtype
performed the worst across cognitive domains, while the
“psychiatric & motor” subtype had the highest depression
and apathy ratings.
PD subtypes also differed on select demographic and
clinical variables at baseline (Table 2). Although the “mo-
tor only” subtype was younger at disease onset and study
enrollment, and had shorter symptom duration than the
“cognitive & motor” subtype, the “psychiatric & motor”
and “cognitive & motor” subtypes did not differ in age
(onset or enrollment), or symptom duration.
The “motor only” subtype had the highest proportion
of females, and the “psychiatric & motor” subtype had
the highest LEDD; however, there were no differences
between groups for number of participants on dopa-
mine agonists. The “cognitive & motor” subtype con-
tained the highest proportion with cognitive impairment
and MCI, whereas the “psychiatric & motor” subtype
reported the most psychiatric symptoms (NPIQ;
Table 2).
Education, presence of anxiety, hallucinations, and con-
stipation were similar across subtypes at baseline
(Table 2). PD subtypes also did not significantly differ on
the BSIT, Epworth, One Day Fluctuations, or orthostasis
(Table 2), although the “cognitive & motor” subtype
demonstrated worse sense of smell and more of the “psy-
chiatric & motor” subtype reported orthostasis. Including
these variables in the discriminant analysis did not
improve group separation or subtype classification
(97.1%, compared to 98.3% with just indicator variables)
and none were selected as significant variables in stepwise
discriminant analyses.
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DBS
Since enrollment, 22 participants underwent DBS surgery.
Subtypes did not differ in proportion (“motor only”: 9/
63, 14.3%; “psychiatric & motor”: 3/17, 17.6%; “cognitive
& motor”: 10/82, 12.2%; v2 = 0.40, P = 0.82) or rate of
DBS surgery (P > 0.26; Table 3, Fig. S2).
Dementia
Thus far, forty-eight participants developed dementia
(CDR ≥ 1). The “cognitive & motor” subtype had the
highest conversion rate (41/82, 50%), followed by “psy-
chiatric & motor” (3/17, 17.6%) and “motor only” sub-
types (4/63, 6.3%) (v2 = 33.9, P < 0.001). Multivariate
Function 1
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Figure 1. PD Clinical Subtypes. (A) LCA analysis identified three distinct PD subtypes based on the pattern of scores across motor, cognitive and
psychiatric domains. Discriminant analyses achieved significant subtype separation and 98.3% classification accuracy based on discriminant
functions 1 and 2, which accounted for 60.5% and 39.5% of the variance, respectively. Group centroid represents the standardized mean scores
for that subtype on function 1 and 2. (B) Subtypes differed across motor, cognitive, and psychiatric measures. Values represent z-scores for each
measure (indicator). Higher scores represent worse function for motor and psychiatric measures; lower scores represent worse function for
cognitive domains. PIGD = postural instability and gait difficulty. Significant subtype differences for all measures, except tremor (P = 0.40) and
memory (P = 0.11).
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Cox proportional hazards regression, controlling for base-
line education, age, sex, symptom duration, and stratified
by baseline CDR score, revealed subtype differences
(v2 = 28.18, P < 0.001; Fig. 2A, Table 3). The “cognitive
& motor” subtype demonstrated a faster dementia con-
version rate compared to the “motor only” (relative risk
[RR] = 4.20; Table 3) and “psychiatric & motor” sub-
types (RR = 3.37). Dementia rates did not differ between
“psychiatric & motor” (RR = 1.25) and “motor only”
subtypes (Fig. 2A).
Mortality
Forty-six participants died since study enrollment
(Table S3), with a higher proportion in the “cognitive &
motor” subtype (N = 36) than the “motor only” (N = 7)
and “psychiatric & motor” (N = 3) subtypes (v2 = 19.92,
P < 0.001). Cause of death (Table S3), “PD-related”
(N = 31) versus “non PD-related” (N = 15), did not dif-
fer between subtypes (v2 = 2.30, P = 0.32).
Multivariate Cox proportional hazards regression, con-
trolling for baseline age, sex, and symptom duration,
revealed different mortality rates across subtypes
(v2 = 24.22, P < 0.001; Fig. 2B). Both the “psychiatric &
motor” and “cognitive & motor” subtypes showed
similarly increased risks of mortality compared to the
“motor only” subtype (RR = 2.60 and 3.15; Table 3;
Fig. 2B).
Twenty-four autopsies confirmed PD diagnosis (12
pending neuropathology results; six without brain dona-
tion; four found not to have idiopathic PD). Excluding
the four non-PD participants (originally classified as
“cognitive & motor”) revealed similar differences in mor-
tality rates across subtypes (Table S4, Fig. S3). The “cog-
nitive & motor” and “psychiatric & motor” subtypes
remained at higher mortality risk (RR = 2.73 and 2.38)
than the “motor only” subtype.
Discussion
Multi-domain LCA identified distinct PD clinical sub-
types: “motor only,” “psychiatric & motor,” and “cogni-
tive & motor”. The remarkably high classification
accuracy (98%) and membership certainty (>90%)
demonstrate the robustness of these subtypes. Utilizing a
multi-domain assessment permitted identification of the
key features that best distinguish subtypes– depression,
executive function, and apathy. Finally, these PD subtypes
yield strong prognostic utility for determining conversion
to dementia and mortality. Interestingly, both the
Table 2. Comparison of PD subtypes on baseline clinical and demographic characteristics.
Variable
Class 1: Class 2: Class 3:
Omnibus P-value
“Motor Only” “Psychiatric & Motor” “Cognitive & Motor”
N = 63 N = 17 N = 82
Sex (% male) 48%bc 77%a 70%a P = 0.01
Age (years) 63.2 (6.3)c 64.5 (8.8) 68.6 (7.6)a P < 0.001
Years of education 16 (2.5) 15 (2.4) 16 (2.5) P = 0.15
Age onset of PD 58.3 (6.6)c 57.4 (8.7) 61.9 (8.4)a P < 0.01
Duration of PD symptoms (years) 5.1 (3.0)c 7.2 (3.9) 6.9 (4.1)a P < 0.01
LEDD 613 (380)b 1004 (664)a 783 (438) P = 0.03
DA agonists (no/yes, % using) 14/49, 22% 3/14, 18% 20/62, 24% P = 0.82
NPIQ total score 1.8 (2.4)bc 4.1 (3.7)a 3.1 (2.9)a P = 0.01
MMSE 29.1 (1.1)c 28.3 (1.4) 27.6 (1.6)a P < 0.001
MCI 3 (4.8%) 2 (11.8%) 21 (25.6%) P = 0.003
CDR (0/.5) 55/8bc 9/8ac 27/55ab P < 0.01
BSIT 7.3 (2.6) 6.4 (2.3) 5.5 (2.3) P = 0.24
Epworth sleepiness 8.9 (4.5) 10.2 (4.7) 9.0 (3.6) P = 0.56
One day fluctuations 0.5 (1.1) 0.8 (1.3) 1.0 (1.7) P = 0.12
Constipation (no/yes, % yes)1 22/35, 56% 3/13, 76% 32/47, 57% P = 0.26
Orthostasis (no/yes, % yes)1 43/14, 22% 10/7, 41% 55/24, 29% P = 0.40
Hallucinations (no/yes, % yes) 63/0, 0% 16/1, 6% 75/7, 9% P = 0.06
Values represent mean (SD), except sex, MCI, CDR, Constipation, and Orthostasis reported as percentage or total number. LEDD, levodopa equiv-
alent daily dose; DA Agonists, Dopamine Agonists; NPIQ, Neuropsychiatric Inventory Questionnaire; MMSE, Mini Mental Status Exam; MCI, Mild
Cognitive Impairment; CDR, Clinical Dementia Rating scale. Superscripts indicate significant differences from (a) motor only; (b) psychiatric &
motor; (c) cognitive & motor (i.e., “ab” indicates significant difference from both “motor only” and “psychiatric & motor” subtypes). Significant
differences (P < 0.05) are marked in bold.
1Total counts reflect only those participants who provided responses to these questions.
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“cognitive & motor” and “psychiatric & motor” subtypes
demonstrated increased mortality risk. These results high-
light the need for clinical evaluations that include ade-
quate cognitive and psychiatric assessment to guide
prognosis. Ultimately, PD clinical subtypes may provide
insight regarding neuropathology and improve patient
selection for clinical trials.
Cognitive and psychiatric features
distinguish subtypes
Psychiatric and cognitive function distinguish the “psychi-
atric & motor” and “cognitive & motor” subtypes. In fact,
depression, executive function, and apathy best discrimi-
nated subtypes. Interestingly, the “psychiatric & motor”
and “cognitive & motor” subtypes did not differ in the
presence of anxiety or hallucinations, further reinforcing
depression and apathy as key psychiatric features. Despite
the high rate of psychiatric comorbidities with PD and
important treatment implications, few multi-domain sub-
typing studies included psychiatric measures.14,15,19 Tre-
mor did not discriminate between subtypes and
bradykinesia contributed more to subtype distinctions
than PIGD, suggesting the classic tremor/PIGD dichotomy
is insufficient. In fact, we achieved 98% classification accu-
racy whereas approximately 20% remained unclassified or
Table 3. PD subtypes predict longitudinal conversion to clinical outcomes.
Model Variables Coefficients Wald Z P-value Multivariate relative risk (95% CI)
DBS surgery1
Covariates Age 0.08 2.57 0.01 0.92 (0.87, 0.98)
Symptom duration 0.02 0.29 0.77 0.98 (0.86, 1.11)
Subtype comparisons "Motor Only" vs. "Psychiatric & Motor" 0.77 1.11 0.27 2.17 (0.55, 8.55)
"Motor Only" vs. "Cognitive & Motor" 0.23 0.47 0.64 1.26 (0.49, 3.24)
"Cognitive & Motor" vs. "Psychiatric & Motor" 0.55 0.78 0.43 0.58 (0.15, 2.27)
Dementia conversion2
Covariates Education 0.07 1.02 0.31 1.07 (0.94–1.23)
Age 0.05 2.30 0.02 1.05 (1.01–1.09)
Sex 0.60 1.68 0.09 0.55 (0.27–1.11)
Symptom Duration 0.02 0.36 0.72 1.02 (0.93–1.11)
Subtype comparisons "Motor Only" vs. "Psychiatric & Motor" 0.22 0.27 0.79 1.25 (0.25–6.28)
"Motor Only" vs. "Cognitive & Motor" 1.44 2.51 0.01 4.20 (1.37–12.88)
"Psychiatric & Motor" vs. "Cognitive & Motor" 1.22 1.97 <0.05 3.37 (1.01–11.30)
Mortality3
Covariates Age 0.06 2.72 0.007 1.06 (1.02–1.11)
Sex 0.41 1.19 0.23 0.66 (0.34–1.30)
Symptom duration 0.00008 0.002 0.99 1.00 (0.92–1.09)
Subtype comparisons "Motor Only" vs. "Psychiatric & Motor" 0.95 1.32 0.19 2.60 (0.63–10.76)
"Motor Only" vs. "Cognitive & Motor" 1.15 2.60 0.009 3.15 (1.33–7.49)
"Psychiatric & Motor" vs. "Cognitive & Motor" 0.19 0.31 0.75 1.21 (0.36–4.09)
Table presents results of longitudinal multivariate Cox proportional hazards regression models comparing baseline PD subtypes in conversion to
clinical milestones of DBS, dementia, and mortality.
1DBS surgery adjusted for age and symptom duration.
2Dementia conversion rate, stratified by baseline CDR, and adjusted for education, age, sex, and symptom duration at baseline.
3Mortality rate adjusted for age, sex and symptom duration at baseline. The first subtype listed refers to the reference group in that analysis (e.g.,
“Motor Only” (reference group) vs. “Psychiatric & Motor”). Significant differences (P < 0.05) are marked in bold.
Figure 2. PD subtypes predict conversion to dementia and mortality. Graphs represent Kaplan-Meier and Cox regression survival plots where “+”
indicates censoring and a vertical drop indicates occurrence of an event, either conversion to dementia (panel A) or mortality (panel B). (A1) Top
graph represents the Kaplan-Meier curve for rate of dementia conversion for each subtype without covariates. Table indicates number of
participants for each subtype at risk of conversion across time. (A2) Bottom graph represents the Cox regression curves predicting dementia
conversion rates for each subtype, accounting for education, sex, age, symptom duration, and CDR score at initial visit, showing a clear difference
in conversion rates between the “cognitive & motor” subtypes and both “motor only” and “psychiatric & motor” subtypes. (B1) Kaplan–Meier
curves for mortality of each subtype without covariates. Table indicates the number of participants for each subtype at risk of mortality across
time. (B2) Bottom graph represents Cox regression curves predicting mortality rates for each subtype, accounting for age, sex, and symptom
duration at initial visit, showing similar mortality rates between “cognitive & motor” and “psychiatric & motor” subtypes that are greater than the
mortality rate of the “motor only” subtype
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indeterminate using the tremor/PIGD classification. These
results emphasize the independent and important contri-
butions of psychiatric and cognitive attributes to the clini-
cal presentations of PD.
Our distinct PD subtypes identify a clinically relevant
psychiatric subtype with increased mortality risk. Recent
subtype classifications emphasize differences in symptom
severity and prognosis (e.g., mild/motor, intermediate,
diffuse/malignant14), suggesting possible disease stages.
Our multi-domain evaluation specifically highlights the
cognitive and psychiatric aspects as the key features that
distinguish subtypes. General screening measures, a single
“non-motor” composite score, or reliance on motor
scores alone may not provide adequate sensitivity and
specificity to classify PD subtypes.
The higher proportion of women in the “motor only”
subtype raises the possibility that female PD patients pre-
sent with different clinical features and progression than
males. Previous studies report sex differences across sub-
types, typically with more females in the most mildly
affected subtype,12,13,15 consistent with our current find-
ings. Additional research on sex differences in PD is needed,
especially given sex differences in healthy brain aging51 and
tau pathology in preclinical Alzheimer disease.52
PD subtypes predict clinical milestones
Prospective, longitudinal follow-up establishes the prog-
nostic utility of these PD subtypes for clinical milestones.
The “cognitive & motor” subtype exhibited faster dementia
conversion as expected, even after accounting for age,
symptom duration, and baseline cognitive status. Cognitive
impairment is well established to precede and predict
dementia.53,54 Surprisingly, both the “cognitive & motor”
and “psychiatric & motor” subtypes had increased mortal-
ity rates, regardless of symptom duration. However, there
were no subtype differences in DBS rates. Increased demen-
tia and mortality risk for the “cognitive & motor” subtype
may be due, in part, to older age at onset and worse cogni-
tion. Previous studies also report subtype differences in
progression,14,19,55 with cognitive and nonmotor symp-
toms, rather than motor, as the strongest predictors of
prognosis.14 However, prognosis was primarily based on a
global composite score14 and not specific to any clinically
relevant milestone. One other prospective study reports
mortality rates,56 with increased mortality associated with
more severely affected subtypes suggesting possible disease
stage effects. Conversely, our data suggest that presence of
cognitive or psychiatric problems increases mortality risk,
regardless of age or symptom duration. Previous research
indicates that psychosis increases mortality risk,57,58 but
our novel results suggest that depression and apathy also
increase mortality risk in Parkinson disease.
Distinct subtypes or different disease
stages?
Symptom duration and motor severity did not differ
between the “cognitive & motor” and “psychiatric & motor”
subtypes, suggesting that these subtypes do not merely
reflect disease stages.7 Further, the “cognitive & motor” and
“psychiatric & motor” subtypes displayed similarly high
mortality risks, but different rates of dementia. Similarity in
DBS rates across subtypes also argues against a disease stage
model. While it remains possible that the “motor only” sub-
type represents an early disease stage, the “cognitive &
motor” and “psychiatric & motor” do not appear to be
sequential PD stages with cumulative symptomatology.
Additional longitudinal analyses are required to determine
subtype stability and progression. Information regarding
neurobiological changes associated with each subtype also
may offer insight into subtype differences and progression.
However, in the final stages of disease (e.g., near death), PD
subtypes may converge in clinical manifestations and neu-
ropathology.5 In vivo neurobiological measures will be cru-
cial for characterizing the temporal progression of disease
pathology in relation to clinical progression.
Strengths & limitations
Using multi-domain LCA, which avoids the limitations of
traditional clustering-based approaches, we identified dis-
tinct PD subtypes and the key distinguishing features,
emphasizing the role of cognitive and psychiatric manifes-
tations. The comprehensive assessment conducted OFF
medication and broad spectrum of nondemented PD pre-
vents potential medication confounds and classification
based on dementia, and permits examination of the pre-
dictive utility of baseline subtypes. Subtype classification
with drug-naive PD patients also would eliminate medica-
tion confounds.2,11,18 However, this would limit analyses
to newly diagnosed PD with fewer clinical features. Inter-
estingly, the “psychiatric & motor” subtype reported the
highest LEDD, suggesting potential medication effects on
clinical presentation or subtype differences in response to
medication.12,19 Finally, the prospective, longitudinal fol-
low-up provides critical information regarding the prog-
nostic utility of PD subtypes for important clinical
milestones, here demonstrating subtype differences in
dementia and mortality.
The lack of a specific anxiety questionnaire and limited
psychiatric assessments represents a potential limitation;
however, PD subtypes did not differ on presence of anxiety,
suggesting that inclusion of anxiety would not substantially
change the PD subtypes. This study, however, did include
apathy, which is rarely assessed in other classifications.12,14
Although we did not include other nonmotor symptoms
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(e.g., fatigue, pain, orthostasis) in our classification, which
also affect quality of life59,60 and could contribute to PD
subtypes,14 subtypes did not significantly differ on sense of
smell, daytime sleepiness, constipation, or orthostasis nor
did these features distinguish subtypes. The relatively low
number of DBS and autopsy cases should be interpreted as
preliminary evidence.
Future directions
Identification and validation of PD subtypes could aid in
prognosis, improve patient selection for clinical trials, and
perhaps even suggest new treatment approaches. The cur-
rent findings provide important information for this
endeavor and reinforce the potential clinical utility of PD
subtypes. Of course, several additional steps would be
required before clinical implementation. First, replication
with an independent cohort is necessary to validate these
PD clinical subtypes and to determine the sensitivity and
specificity to classify at the individual level. Second, the
longitudinal progression and stability of PD subtypes
remains to be determined. Additional areas of future
research should also include examination of potential
subtype differences in neuropathology and treatment
response.
Conclusion
Psychiatric and cognitive features drive PD subtypes,
rather than motor deficits alone. These results demon-
strate the value of multi-domain classification including
cognitive and psychiatric measures to better characterize
clinical variability in PD. Further, the differences in
dementia and mortality rates across subtypes demonstrate
the prognostic utility of these PD subtypes.
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